Medicover completed the acquisition of a 68.3% stake in NIPD Genetics for $51m.

Medicover, a specialised provider of diagnostic and healthcare services, completed the acquisition of a 68.3% stake in NIPD Genetics, a European biotechnology company, for $51m. “NIPD’s proprietary technology platform together with their experienced expert team and Medicover Genetics state-of-the art diagnostics will take us one step closer to become an international market leader in genetic diagnostics”, Fredrik Rågmark, Medicover CEO.